Cureline AG belongs to Cureline Group, precision medicine CRO of Californian origin and global reach. In 20 years of its history, Cureline Group became a best-in-class expert in oncology human sample validation studies (HBS biobanking), in vitro and animal testing. New venture: ATMP CDMO (EU).
Products, services, technology
oncology human sample validation studies (HBS biobanking) - in vitro testing and animal testing - preclinical models - gene and cell therapy (as of 2024) - concierge services along the whole process of drug development (with our partner in clinical space, Wiesbaden based company palleos)
Our R&D areas include gene and cell therapy, exosome research, 3D organoids. We are interested in discussing possible collaborations also in those areas. We welcome investors to join efforts on innovative CRO equity solutions, gene and cell therapy development.
Cureline's mission is to work towards shaping the future of healthcare and precision medicine through delivering life-changing advanced therapies to the world.
Cureline Group steadfastly delivers profitable organic growth since 20 years by adding new geographies and innovative customer solutions.
Investors, collaboration partners